

Pre-Conference Symposium: Medical Device Investor Day June 23
Do-Not-Miss Large Co. Presentations by Covidien, Boston Scientific, BD and many others

“Investment In Innovation (In³)”

A PREVIEW OF EARLY-STAGE MEDTECH COMPANIES

June 23-25, 2009

Westin Copley Place, Boston



“The quality and quantity of investors who attend In3 events is impressive. From an emerging company’s point of view, the cost of participating is nominal compared to the potential upside of persuading just one investor to take a close look at you.”

Christof Lenz
Chief Executive Officer
Cardiola



“We are pioneering what could be the first nontoxic product for the treatment of cancer. This is truly cutting-edge technology that is appreciated by the well-informed investors we meet at Medtech Insight conferences.”

Dr. Laurent Lévy
Chief Executive Officer
Nanobiotix



“Our initial product, Surinate®, is designed to significantly improve the plight of men suffering from acute or chronic urinary retention. We are pleased to have presented our story at the premier medtech-focused event for investors.”

Dr. Harvey Homan
Chief Executive Officer
Urovalve

Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. (www.ronaldtrahan.com), a public relations/investor relations firm that serves big and small companies, both public and private.



Percutaneous *Mitral* Valve Replacement (PMVR) technology to be showcased

by Ronald C. Trahan

CardiaQ Valve Technologies (CVT), a Boston-area medtech company developing innovative approaches to heart valve replacement, is initially focused on **Percutaneous Mitral Valve Replacement (PMVR)**. There are more than two million people who suffer from **Mitral Regurgitation (MR)**, yet only about 80,000 repair or replacement procedures take place each year. The significant treatment gap is largely due to the risk associated with the currently available surgical procedures. While several companies are attempting to develop percutaneous approaches to *repair* the mitral valve, these repair



J. Brent Ratz
President and CEO,
CardiaQ Valve
Technologies (CVT)

technologies have limited applicability due to the heterogeneous nature of the disease and, so far, have had a difficult time demonstrating efficacy that is equivalent to surgical approaches. Likewise, there are a number of technologies under development for *catheter*-based replacement of aortic valves; however, all of these technologies rely on *radial force* for fixation in a highly calcified valve, which is not suitable for the mitral position. **CVT may be the only company developing a percutaneous replacement approach to MR.** CVT’s unique **fixation** and **positioning** technology platform allows the Company to compete where others cannot.

As a result, CVT believes that its **PMVR** system will provide a faster, safer, and less-invasive alternative to traditional mitral valve surgery, while providing broader applicability and greater effectiveness than the other catheter-based technologies under development. “No other heart valve company has a frame that is *self-positioning*, *self-anchoring*, and *self-conforming* in three dimensions. CVT’s technology has the unique potential to treat aortic stenosis, aortic regurgitation, and mitral regurgitation,” says **Joseph Bavaria, MD**, Vice Chief, Cardiothoracic Surgery, Hospital of Pennsylvania; Professor of Surgery, UPenn; Principal Investigator, Edwards Lifesciences PARTNER trans-catheter aortic valve trial; member, St. Jude Medical’s Structural Heart Advisory Board; and, Chairman of CVT’s Scientific Advisory Board. “In vivo feasibility studies strongly suggest that CVT’s initial focus on PMVR may provide effective treatment of MR (mitral regurgitation).” ■

Investment In Innovation (In³) East:

A Preview of Early-Stage Medical Technology Companies
Medtech Insight’s 35th Investment & Partnering Event!

The Westin Copley Place, Boston, Massachusetts, June 23-25, 2009

Medtech Insight’s conferences have drawn over 8,500 attendees and more than 1,500 innovative, early stage presenting companies during the past 8 years—making them the premier investment, partnering, and networking event in the medical technology industry. *In³ East* will feature a new group of over 50 early-stage medical technology companies seeking partnering and/or investment.

To register for this conference, please call **Kristy Grimes** at **480-985-9512** or **888-202-5939** (toll-free in the U.S.), or send an email to in3@windhover.com.